Publications
5808 Results
- Journal / Conference
- PLoS One Dec 27;12(12):e0187741
- Year
- 2017
- Research Committee(s)
- Cancer Control, Prevention, Screening, and Surveillance, Prevention, Screening, and and Surveillance
- PMID
- PMID29281666
- PMC
- PMC5744924
- Study Number(s)
- S0000, SWOG-9217
Circulating sex hormones in relation to anthropometric, sociodemographic and behavioural factors in an international dataset of 12,300 men
- Journal / Conference
- Journal of Clinical Oncology Nov 10;35(32):3671-3677
- Year
- 2017
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID28976791
- PMC
- PMC5678342
Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance)
- Journal / Conference
- Kidney Cancer Nov 27;1(2):123-132
- Year
- 2017
- Research Committee(s)
- Genitourinary
- PMID
- PMID30334014
- PMC
- PMC6179121
- Study Number(s)
- S1107
Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107
- Journal / Conference
- JCO Clinical Cancer Informatics Nov;1:1-12; DOI: https://doi.org/10.1200/CCI.17.00040 Publishedonlineonascopubs.org/journal/ccion November 20, 2017.
- Year
- 2017
- Research Committee(s)
- Breast, Gastrointestinal, Genitourinary, Lung, Myeloma, and Sarcoma
- PMID
- PMID30657402
- PMC
- PMC6640843
- Study Number(s)
- S0003, S0023, S0033, S0124, S0205, S0221, S0226, S0232, S0307, S0421, S0500, S0777, SWOG-9321, SWOG-9346, S9916
History of diabetes and outcome among participants 65 or older in SWOG clinical trials
- Journal / Conference
- Annals of Oncology Jun 1;28(suppl_3) LBA
- Year
- 2017
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/N0147
Evaluation of immunoscore and immune biomarkers in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance)
- Journal / Conference
- Future Oncology Jun;13(13):1181-1193
- Year
- 2017
- Research Committee(s)
- Leukemia and Myeloma
- PMID
- PMID28395525
- PMC
- PMC5705823
- Study Number(s)
- S0106, SWOG-9321
End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma.
- Journal / Conference
- NPJ Breast Cancer Aug 10;2:16024
- Year
- 2016
- Research Committee(s)
- Breast
- PMID
- PMID28721383
- PMC
- PMC5515330
- Study Number(s)
- S9630
A phase III randomized comparison of medroxyprogesterone acetate versus observation for the prevention of endometrial pathology in postmenopausal patients with breast cancer treated with adjuvant tamoxifen: SWOG S9630
- Journal / Conference
- Trials 17:400
- Year
- 2016
- Research Committee(s)
- Prevention, Screening, and and Surveillance
- PMID
- PMID27519183
- PMC
- PMC4983010
- Study Number(s)
- S0000
Opportunities and challenges in incorporating ancillary studies into a cancer prevention randomized clinical trial
- Journal / Conference
- NPJ Breast Cancer 2016;2. pii: 15023. doi: 10.1038/npjbcancer.2015.23.
- Year
- 2016
- Research Committee(s)
- Breast
- PMID
- PMID28691057
- PMC
- PMC5501351
- Study Number(s)
- C9741
PAM50 gene signatures are prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy in C9741 (Alliance)
- Journal / Conference
- Leukemia Aug;30(8):1779-1780; 2016 Feb 29 [Epub ahead of print]
- Year
- 2016
- Research Committee(s)
- Leukemia
- PMID
- PMID27055872
- PMC
- PMC4980556
- Study Number(s)
- S0106, SWOG-8600, SWOG-9031, SWOG-9333